MVEC eLearning: Use of Multi-Dose Vials

MVEC are excited to launch the next of our eLearning packages. Our eLearning packages are designed to allow immunisation providers consolidate and evaluate their technical skills. Targeted resources are available to assist with our eLearning and a certificate of completion will be made available upon completion of the corresponding eLearning quiz.

Use of Multi-Dose Vials has been designed to demonstrate the safe preparation and storage of vaccines from multi-dose vials that require reconstitution and from those that do not.

You can access Use of Multi-Dose Vials via our Education Portal.

Community pharmacies to participate in COVID-19 vaccination program

The Australian Government has announced an expression of interest (EOI) process has begun for community pharmacies to participate in the COVID-19 vaccination program.

Participation is voluntary, with pharmacies needing to demonstrate their capacity, capability and ability to meet high safety standards.

Eligible pharmacies would be able to deliver COVID-19 vaccines to priority populations from phase 2a of the of Australian COVID-19 vaccination rollout strategy (expected to be in May 2021). They would be incentivised to provide both doses of the AstraZeneca COVID-19 vaccine in an effort to increase uptake of the vaccine.

Read more about this in the Health Minister’s statement via the link below:

Community Pharmacy to join COVID-19 vaccine workforce

Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial

Novavax have released interim results for both its UK phase III clinical trial as well as for the phase 2b studies being conducted in South Africa.

The UK phase III clinical trial involves more than 15,000 participants aged 18-84 years. During a period of high transmission with the UK variant of SARS-CoV-2, the preliminary results show an efficacy rate of 89.3%. After review of the vaccine safety database it has also been reported that any adverse events were balanced between both the vaccine and the placebo groups and any serious or severe side effects occurred at low levels.

In the South African phase 2b clinical trial, an efficacy rate of 60% was seen in the HIV-negative cohort, with an overall 49.4% efficacy rate seen across the total 4,400 trial participants (both HIV-negative and HIV positive individuals). During the time of the trial, the South African variant of SARS-CoV-2 was widely circulating.

The Novavax COVID-19 vaccine candidate is a protein-based vaccine utilising a nanoparticle technology platform.

To read the full press release follow the link below:

Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial